The article highlights the significant advancements in science leading to potential treatments for rare diseases, such as gene therapies and drugs affecting gene expression, which were previously unimaginable. However, many rare diseases still lack treatment options, necessitating further efforts to alleviate patient and family suffering.

To address this, the FDA has launched the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) Pilot Program, spearheaded by the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER). The START Pilot Program aims to accelerate the development of novel drugs and biologics for rare diseases by providing selected participants with frequent, tailored advice from FDA staff. This guidance covers product-specific development issues, clinical study design, control group selection, and patient population choice.

The program seeks to:

  1. Facilitate efficient development of potentially life-saving therapies.
  2. Help sponsors generate high-quality, actionable data for future drug or biologics license applications.
  3. Address early development issues that could delay or halt the progression of promising products to pivotal clinical trials.
  4. Ensure clear understanding of the necessary information and data to support product development.

Overall, the START Pilot Program aims to expedite the availability of treatments for rare diseases by enhancing the development process through increased interaction and guidance from the FDA.1

You can read the full text here.

References

  1. Research, C. F. D. E. A. (2024, June 27). FDA Opens Doors for More Treatments for Rare Diseases through the New  START Pilot Program. U.S. Food And Drug Administration. https://www.fda.gov/drugs/our-perspective/fda-opens-doors-more-treatments-rare-diseases-through-new-start-pilot-program

Disclaimers

  • The material in these reviews is from various public open-access sources, meant for educational and informational purposes only
  • Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
  • No official support by any organization(s) has been provided or should be inferred